ProMIS Neurosciences Announces Up To $122.7M Private Placement Financing; Proceeds Expected To Support Company Beyond 6 Month And 12 Month Data From The PMN310 Phase Ib Study In Alzheimer's Patients
ProMIS Neurosciences Announces Up To $122.7M Private Placement Financing; Proceeds Expected To Support Company Beyond 6 Month And 12 Month Data From The PMN310 Phase Ib Study In Alzheimer's Patients
TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 26, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN) ("ProMIS" or the "Company"), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that it has entered into a unit purchase agreement with certain new and existing institutional and accredited investors to issue and sell an aggregate of approximately $30.3 million of (a) common share units (the "Common Share Units"), with each Common Share Unit consisting of (i) one Common Share, without par value (a "Common Share"), (ii) one Tranche A Common Share purchase warrant to purchase one Common Share, (iii) one Tranche B Common Share purchase warrant to purchase one Common Share and (iv) one Tranche C Common Share purchase warrant to purchase one Common Share (each, a "Warrant", collectively, the "Warrants") and, for certain investors, (b) pre-funded units (the "Pre-Funded Units", and together with the Common Share Units, the "Units"), with each Pre-Funded Unit consisting of (i) one Pre-Funded Warrant to purchase one Common Share, (ii) one Tranche A Common Share purchase warrant to purchase one Common Share, (iii) one Tranche B Common Share purchase warrant to purchase one Common Share and (iv) one Tranche C Common Share purchase warrant to purchase one Common Share. The Common Share Units were sold at a price of $2.15 per Unit and the Pre-Funded Units were sold at a price of $2.14 per Unit through a private investment in public equity ("PIPE") financing.$30.3 million financing upfront with up to an additional $92.4 million tied to exercise of warrants, with certain of the warrants subject to shareholder approval
$3030萬的融資款將預先支付，並有高達$9240萬與認股權的行權相關聯，其中某些認股權需股東批准。
Fundraise supports development of novel antibody PMN310 for Alzheimer's Disease patients
籌款支持新型抗體PMN310用於治療阿爾茨海默病患者的開發。
Proceeds expected to support Company beyond 6 month and 12 month data from the PMN310 Phase Ib study in Alzheimer's patients
資金將用於PMN310階段Ib研究中關於治療阿爾茨海默病患者6個月和12個月數據之後的公司發展。
TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 26, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN) ("ProMIS" or the "Company"), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that it has entered into a unit purchase agreement with certain new and existing institutional and accredited investors to issue and sell an aggregate of approximately $30.3 million of (a) common share units (the "Common Share Units"), with each Common Share Unit consisting of (i) one Common Share, without par value (a "Common Share"), (ii) one Tranche A Common Share purchase warrant to purchase one Common Share, (iii) one Tranche B Common Share purchase warrant to purchase one Common Share and (iv) one Tranche C Common Share purchase warrant to purchase one Common Share (each, a "Warrant", collectively, the "Warrants") and, for certain investors, (b) pre-funded units (the "Pre-Funded Units", and together with the Common Share Units, the "Units"), with each Pre-Funded Unit consisting of (i) one Pre-Funded Warrant to purchase one Common Share, (ii) one Tranche A Common Share purchase warrant to purchase one Common Share, (iii) one Tranche B Common Share purchase warrant to purchase one Common Share and (iv) one Tranche C Common Share purchase warrant to purchase one Common Share. The Common Share Units were sold at a price of $2.15 per Unit and the Pre-Funded Units were sold at a price of $2.14 per Unit through a private investment in public equity ("PIPE") financing.
加拿大安大略省和馬薩諸塞州劍橋市，2024年7月26日（全球新聞社）- 生物技術公司ProMIS Neurosciences Inc.（納斯達克上市公司：PMN）（“ProMIS”或“公司”）專注於生成和開發針對神經退行性疾病（如阿爾茨海默病（AD），肌萎縮性側索硬化症（ALS）和多系統萎縮（MSA））中有毒錯折蛋白的抗體治療方法，今天宣佈已與某些新投資方和現有機構投資者簽訂了一項單位購買協議，以發行約$3030萬的（a）普通股單位（“普通股單位”），每個普通股單位包括（i）一股無面值普通股（“普通股”），（ii）一份Tranche A普通股購買認股權，可購買一股普通股，（iii）一份Tranche b普通股購買認股權，可購買一股普通股，以及（iv）一份Tranche C普通股購買認股權，可購買一股普通股（每份認股證書均稱爲“認股權證”，統稱爲“認股權”），以及（b）對於某些投資者，預先融資單位（“預先融資單位”） ，每個預先融資單位包括（i）一份預先融資認股權，可購買一股普通股，（ii）一份Tranche A普通股購買認股權，可購買一股普通股，（iii）一份Tranche b普通股購買認股權，可購買一股普通股，以及（iv）一份Tranche C普通股購買認股權，可購買一股普通股。普通股單位的發售價格爲每單位$2.15，預先融資單位的發售價格爲每單位$2.14（通過私募股權投資進行融資）。
譯文內容由第三人軟體翻譯。